Jagsonpal Pharmaceuticals (India) Price on November 14, 2024
| JAGSNPHARM | 636.65 9.80 1.52% |
Below is the normalized historical share price chart for Jagsonpal Pharmaceuticals Limited extending back to July 01, 2002. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Jagsonpal Pharmaceuticals stands at 636.65, as last reported on the 26th of December, with the highest price reaching 669.95 and the lowest price hitting 630.60 during the day.
If you're considering investing in Jagsonpal Stock, it is important to understand the factors that can impact its price. Jagsonpal Pharmaceuticals appears to be very steady, given 3 months investment horizon. Jagsonpal Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.18, which attests that the entity had a 0.18% return per unit of risk over the last 3 months. By evaluating Jagsonpal Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.78% is justified by implied risk. Please utilize Jagsonpal Pharmaceuticals' Risk Adjusted Performance of 0.1527, downside deviation of 3.07, and Market Risk Adjusted Performance of 0.766 to validate if our risk estimates are consistent with your expectations.
As of now, Jagsonpal Pharmaceuticals' Common Stock Shares Outstanding is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Common Stock is estimated to increase to about 144.2 M, while Total Stockholder Equity is projected to decrease to under 1.2 B. . Jagsonpal Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
200 Day MA 416.7065 | 50 Day MA 598.427 | Beta 1.055 |
Jagsonpal |
Sharpe Ratio = 0.183
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | JAGSNPHARM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.78 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Jagsonpal Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Jagsonpal Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 8.5744 | Book Value 74.422 | Enterprise Value 16.3 B | Enterprise Value Ebitda 43.5588 | Price Sales 7.4764 |
Jagsonpal Pharmaceuticals Valuation on November 14, 2024
It is possible to determine the worth of Jagsonpal Pharmaceuticals on a given historical date. On November 14, 2024 Jagsonpal was worth 533.6 at the beginning of the trading date compared to the closed value of 533.5. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Jagsonpal Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Jagsonpal Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Jagsonpal Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Jagsonpal Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 559.10 | 571.95 | 525.75 | 532.00 | 60,964 | |
11/14/2024 | 533.60 | 550.00 | 527.30 | 533.50 | 43,064 |
| 533.50 | 599.00 | 533.50 | 591.10 | 125,001 |
| Backtest Jagsonpal Pharmaceuticals | | | Jagsonpal Pharmaceuticals History | | | Jagsonpal Pharmaceuticals Valuation | Previous | Next |
Jagsonpal Pharmaceuticals Trading Date Momentum on November 14, 2024
| On November 18 2024 Jagsonpal Pharmaceuticals Limited was traded for 591.10 at the closing time. The highest price during the trading period was 599.00 and the lowest recorded bid was listed for 533.50 . The volume for the day was 125 K. This history from November 18, 2024 contributed to the next trading day price growth. The trading delta at closing time to the next closing price was 10.80% . The trading delta at closing time to the current price is 21.46% . |
Jagsonpal Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Jagsonpal Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Jagsonpal Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Jagsonpal financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Jagsonpal Pharmaceuticals Stock history
Jagsonpal Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Jagsonpal is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Jagsonpal Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Jagsonpal Pharmaceuticals stock prices may prove useful in developing a viable investing in Jagsonpal Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 26.6 M | 28.8 M | |
| Net Income Applicable To Common Shares | 307.3 M | 322.7 M |
Jagsonpal Pharmaceuticals Quarterly Net Working Capital |
|
Jagsonpal Pharmaceuticals Stock Technical Analysis
Jagsonpal Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Jagsonpal Pharmaceuticals Period Price Range
Low | December 26, 2024
| High |
0.00 | 0.00 |
Jagsonpal Pharmaceuticals Limited cannot be verified against its exchange. Please verify the symbol is currently traded on National Stock Exchange of India. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Jagsonpal Pharmaceuticals December 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Jagsonpal Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Jagsonpal Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Jagsonpal Pharmaceuticals stock market strength indicators, traders can identify Jagsonpal Pharmaceuticals Limited entry and exit signals to maximize returns
Jagsonpal Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Jagsonpal Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Jagsonpal Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Jagsonpal to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1527 | |||
| Jensen Alpha | 0.7068 | |||
| Total Risk Alpha | 0.5606 | |||
| Sortino Ratio | 0.2298 | |||
| Treynor Ratio | 0.756 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Jagsonpal Stock analysis
When running Jagsonpal Pharmaceuticals' price analysis, check to measure Jagsonpal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jagsonpal Pharmaceuticals is operating at the current time. Most of Jagsonpal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jagsonpal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jagsonpal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jagsonpal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |